NEW YORK (GenomeWeb News) – Exosome Diagnostics has made three appointments to its executive team, including appointing David Okrongly to be chief operating officer, Michael Donovan to be chief medical officer, and Sally Bowden to be director of regulatory affairs. The company also named Raphael Bueno, associate chief of cardiothoracic surgery at Harvard University, and Michael Manyak, executive director of global medical affairs at GlaxoSmithKline, to its scientific advisory board.
Okrongly formerly was president and CEO of Quanterix and he was leader of global R&D for Bayer Diagnostics. Donovan previously was chief scientific officer at Aureon Biosciences, senior director of molecular pathology at Millenium Pharmaceuticals, and senior VP at Incyte Genomics. Bowden formerly was VP of quality systems and process improvement at Ventana Medical Systems and VP of regulatory compliance at Roche Diagnostics.
Michael Glynn has been appointed chief commercial officer at Pacific Biosciences. He joins PacBio from Genzyme, where he served as the regional president of Japan and Asia Pacific, and also as a senior vice president. Previously, he spent seven years at Boston Scientific, including serving as president of its Endovations division in the US. He also held various roles at Memtec, Baxter International, Burroughs Wellcome, Estee Lauder, and Elizabeth Arden.
David Ledbetter has joined CombiMatrix's medical advisory board. Ledbetter is a director of the International Standards for Cytogenomic Arrays Consortium and currently serves as the executive vice president and chief scientific officer at Geisinger Health System. He also has held academic and genetics-related positions at Emory University School of Medicine, the University of Chicago, the National Institutes of Health, and Baylor College of Medicine. He is a founding fellow of the American College of Medical Genetics and has served on the boards of directors of the American Society of Human Genetics and the ACMG.
Sequencing services company GeneWiz has appointed Andre Kotz to be European business development manager, a post that will be based in the firm's new office in the UK.
Cathy Dickinson will not stand for re-election to Becton Dickinson's board of directors at its 2012 shareholder meeting, the company said this week.
Vermillion said this week that company CEO, President, and Chair of the Board Gail Page has resigned her position as chair because the company decided to separate the post from the CEO office. The company has elected James Burns to replace Page as board chairman.
Zygem has tapped Gary Levine to be CFO and has hired Jeffrey Hickey to be director of reagents development for forensics. Levine formerly was CFO and treasurer for Bostwick Laboratories and he has been a senior executive with Pfizer and Medco Health Solutions. Hickey recently managed DNA casework for the Armed Forces Medical Examiner System, he was a senior forensic analyst for the National Institute of Justice, Investigative and Forensic Sciences, and he worked at Orchid Cellmark.
Life sciences research and diagnostics company BioChain has appointed Chuanbo Xu to be its chief business development officer. Xu has worked in senior management positions at Abbott and GlaxoSmithKline.
Synthetic Genomics Vaccines, which focuses on developing vaccines using sequencing and synthetic genomic technologies, has appointed Sammy Farah as president. Farah joins the company from Immune Design, where he was chief business officer. Previously, he was at Versant Ventures, where he specialized in biotechnology investing, and at Merck, where he led technology support for multiple commercial vaccines.
Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.